Robert A. Jolly

Robert A. Jolly

Auto-generated profile, based on publicly available information

Robert A. Jolly

Eli Lilly and Company, Lilly Research Laboratories

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
RJRobert Jolly
Robert Jolly
KAKausar Begam Riaz Ahmed
Kausar Begam Riaz Ahmed
CZCraig Zwickl
Craig Zwickl
IWIan Watson
Ian Watson
VGVijay Gombar
Vijay Gombar

4 July 2024 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
RJRobert A. Jolly
Robert A. Jolly
PCPaul D. Cornwell
Paul D. Cornwell
JNJessica Noteboom
Jessica Noteboom
FSFareed Bhasha Sayyed
Fareed Bhasha Sayyed
BTBishnu Thapa
Bishnu Thapa
LBLorrene A. Buckley
Lorrene A. Buckley

1 January 1991 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
GWGrushenka H.I. Wolfgang
Grushenka H.I. Wolfgang
RJRobert A. Jolly
Robert A. Jolly
TPThomas W. Petry
Thomas W. Petry

1 August 2016 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
EHEileen P. Hayes
Eileen P. Hayes
RJRobert A. Jolly
Robert A. Jolly
EFEllen C. Faria
Ellen C. Faria
EBEster Lovsin Barle
Ester Lovsin Barle
JBJoel P. Bercu
Joel P. Bercu
PWPatricia A. Weideman
Patricia A. Weideman

28 May 2024 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
SDSriman De
Sriman De
BTBishnu Thapa
Bishnu Thapa
FSFareed Bhasha Sayyed
Fareed Bhasha Sayyed
SFScott A. Frank
Scott A. Frank
PCPaul D. Cornwell
Paul D. Cornwell
RJRobert A. Jolly
Robert A. Jolly

30 January 2026 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
RJRobert A. Jolly
Robert A. Jolly
ATAlejandra Trejo-Martin
Alejandra Trejo-Martin
JBJoel P. Bercu
Joel P. Bercu
MPMark W. Powley
Mark W. Powley
RTRachael E. Tennant
Rachael E. Tennant
RPRaechel Puglisi
Raechel Puglisi
Nitrosamines (NAs) are a diverse class of mutagenic impurities encompassing both small molecules and structurally complex drug-related NAs, referred to as nitrosamine drug substance-related impurities (NDSRIs). NAs display a broad range of carcinogenic potential, from high carcinogenic potency to being weak or even non-carcinogenic. In vitro Ames tests, conducted with both rat and hamster liver-induced S9, and in vivo transgenic rodent (TGR) mutation assays have been used by pharmaceutical sponsors for hazard identification of NDSRIs. A comparative analysis of Ames tests and TGR results for 33 NDSRIs was performed and revealed an accuracy of 79 % between the overall mutagenic calls in the two assays. For NDSRIs with positive TGR results, mutagenic potency estimates were calculated and compared to NAs with robust carcinogenicity and TGR dose-response data. Results from these NAs demonstrated a strong correlation between carcinogenic potency (TD50) and TGR mutagenic potency (BMDL50) (r2 = 0.95), which supports the use of TGR data for both hazard identification and acceptable intake (AI) determination. By integrating quantitative risk assessment tools with TGR assays, this work contributes to a more robust framework for evaluating NA-associated risks.